MedTrace Logo

Bortezomib With Steroid Pulse Therapy for Acute Cellular Rejection in Kidney Transplantation

NCT02351427 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-02-04

No results posted yet for this study

Summary

The purpose of this study is to determine whether bortezomib is effective in the treatment of acute cellular rejection after kidney transplantation.

Conditions

  • Kidney Transplantation

Interventions

DRUG

Bortezomib

In one group, investigators administer bortezomib and steroid to manage acute cellular rejection in kidney transplantation, and compare the results with another group in which only steroid was administered.

DRUG

Steroid

Investigators administer steroid in both groups for conventional treatment of acute cellular rejection.

Sponsors & Collaborators

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Su-Kil Park, M.D., PhD · Division of Nephrology, Department of Internal Medicine, Asan Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02351427 on ClinicalTrials.gov